BioCentury | Sep 7, 2015
Company News

Cellectis S.A, University of Texas MD Anderson Cancer Center deal

...clinical testing within the next 12 months. The partners will develop UCARTCS1 , UCART22 and UCART38...
...UCARTCS1 targets SLAM family member 7 ( SLAMF7 ; CS1 ), UCART22 targets CD22 and UCART38...
BioCentury | Sep 4, 2015
Company News

MD Anderson, Cellectis enter CAR T collaboration

...clinical testing within the next 12 months. The partners will develop UCARTCS1 , UCART22 and UCART38...
...UCARTCS1 targets SLAM family member 7 ( SLAMF7 ; CS1 ), UCART22 targets CD22 and UCART38...
Items per page:
1 - 2 of 2